In the phase I/II KRYSTAL-1 study on 116 cancer patients carrying KRAS G12C mutations, 42.9% demonstrated confirmed objective responses, with a median duration of 8.5 months, progression-free survival of 6.5 months, and overall survival reaching 12.6 months [42]. The gene discussed is KRAS; the disease is cancer.